We demonstrated that the human IL-2 covalently modified by anti-human IL-2 antibody suppresses the cellular and humoral immunity and controls the disease progression in animal models of ulcerative colitis (UC) and SLE. Here, IL2 is linked to systemic lupus erythematosus.